Financial Analysis: Iqvia (IQV) versus Its Peers
Iqvia (NYSE: IQV) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Iqvia to similar businesses based on the strength of its institutional ownership, risk, profitability, dividends, analyst recommendations, valuation and earnings.
Volatility and Risk
Iqvia has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Iqvia’s competitors have a beta of 1.47, indicating that their average share price is 47% more volatile than the S&P 500.
This table compares Iqvia and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Iqvia and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Iqvia||$6.88 billion||$115.00 million||340.00|
|Iqvia Competitors||$217.40 million||-$39.40 million||-86.64|
Iqvia has higher revenue and earnings than its competitors. Iqvia is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
95.8% of Iqvia shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.4% of Iqvia shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current recommendations and price targets for Iqvia and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iqvia currently has a consensus target price of $106.06, indicating a potential upside of 7.56%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 23.63%. Given Iqvia’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Iqvia has less favorable growth aspects than its competitors.
Iqvia beats its competitors on 7 of the 13 factors compared.
Iqvia Company Profile
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with Analyst Ratings Network's FREE daily email newsletter.